Documentos de Académico
Documentos de Profesional
Documentos de Cultura
ARCHIVOS DE LA SOCIEDAD
ESPAÑOLA DE OFTALMOLOGÍA
www.elsevier.es/oftalmologia
Short communication
a r t i c l e i n f o a b s t r a c t
Article history: Objective/methods: Cases are presented of 4 patients suffering from severe symptoms due to
Received 7 August 2015 ocular psoriasis and who were treated with off-label 0.03% tacrolimus once a day.
Accepted 19 March 2016 Results/conclusions: All four patients had a mixed blepharitis and keratitis. Pseudopterygium
Available online 6 July 2016 and corneal opacities were present in three of them. All of them experienced an improve-
ment of their itching and ocular surface. They all referred to a marked improvement of their
Keywords: quality of life in a follow-up period ranging from six months to two years. Therefore, topical
Tacrolimus tacrolimus could be considered an option in the treatment of ocular psoriasis.
Ocular psoriasis © 2016 Sociedad Española de Oftalmologı́a. Published by Elsevier España, S.L.U. All rights
Psoriasis reserved.
Blepharitis
Pseudopterygium
r e s u m e n
Palabras clave: Objetivo/método: Presentamos una serie de 4 pacientes afectos de psoriasis ocular con sin-
Tacrolimus tomatología severa, a los que se indicó tratamiento off label con tacrolimus tópico al 0,03%
Psoriasis ocular una vez al día.
Psoriasis Resultados/conclusión: La blefaritis mixta y queratitis es común a los 4, y en 3 casos hay seu-
Blefaritis dopterigión y opacidades corneales. Se apreció mejoría subjetiva del prurito en 2 semanas,
Seudopterigión y al mes mejoría de la superficie. Todos manifiestan mejoría significativa de su calidad de
vida tras un rango de seguimiento de 6 meses a 2 años. El tacrolimus tópico puede ser
considerado una opción en el tratamiento de la psoriasis ocular.
© 2016 Sociedad Española de Oftalmologı́a. Publicado por Elsevier España, S.L.U. Todos
los derechos reservados.
夽
Please cite this article as: Rodríguez-Ausín P, Antolín-Garcia D, Ruano del Salado M, Hita-Antón C. Tacrolimus tópico al 0,03% en el
tratamiento de la psoriasis ocular. Arch Soc Esp Oftalmol. 2016;91:505–507.
∗
Corresponding author.
E-mail address: pazrausin@telefonica.net (P. Rodríguez-Ausín).
2173-5794/© 2016 Sociedad Española de Oftalmologı́a. Published by Elsevier España, S.L.U. All rights reserved.
506 a r c h s o c e s p o f t a l m o l . 2 0 1 6;9 1(1 0):505–507
Introduction
Patients
Discussion
tacrolimus. Nonspecific chronic conjunctivitis and/or yellow- corticoid treatment.4–6 To date, local or systemic side effects
reddish plaque can appear on the palpebral conjunctiva and attributable to the use of tacrolimus on the ocular surface have
in addition 18% of patients suffer dry eye due to lacrimal not published. By way of conclusion, 0.03% topical tacrolimus
gland involvement as in other selfimmune systemic diseases.2 could be an efficient and well tolerated therapeutic option for
Corneal disease is very rare, normally secondary to dry eye ocular psoriasis when it has a negative repercussion on the
and trichiasis. The most common finding is keratitis punctata, quality of life of patients.
although the clinic range comprises opacities, sterile infil-
trates, neovascularization, cicatrization and severe peripheral
ulcerative keratitis.3
Conflict of interests
Additional ocular involvement of psoriasis includes ante-
No conflict of interests was declared by the authors.
rior uveitis and Birdshot chorioretinopathy. The side effects of
psoriasis treatments cannot be dismissed, such as isotretinoin
and methotrexate, with possible involvement of the ocular references
posterior pole by the former (neuropathy, maculopathy) and
keratitis and dry eye by the latter. Doxycycline should not be
utilized simultaneously with isotretinoin as it increases its 1. Sousa LB, Bass LJ. Psoriasis. In: Mannis MJ, Macsai MS, Huntley
AC, editors. Eye and skin disease. Philadelphia:
neurological toxicity.
Lippincot-Raven Publishers; 1996. p. 319–26.
The 4 patients of the series have chronic blepharitis, 3 with
2. Rehal B, Modjtahedi BS, Morse LS, Schwab IR, Maibach HI.
a significant corneal involvement that indicates chronicity Ocular psoriasis. J Am Acad Dermatol. 2011;65:1202–12.
such as circumferential pseudopterygium. The main symp- 3. Huynh N, Cervantes-Castaneda RA, Bhat P, Gallagher MJ, Foster
tom is ocular and palpebral pruritus, which improves slightly CS. Biologic response modifier therapy for psoriatic ocular
with palpebral hygiene, heat and massage and more with oral inflammatory disease. Ocul Immunol Inflamm. 2008;16:
doxycycline and corticoids. Relapse upon suspension of this 89–93.
4. Miyazaki D, Tominaga T, Kakimaru-Hasegawa A, Nagata Y,
treatment indicates an efficient anti-inflammatory therapy
Hasegawa J, Inoue Y. Therapeutic effects of tacrolimus
with less side effects than corticoids. ointment for refractory ocular surface inflammatory diseases.
Tacrolimus, Protopic® (Astellas Pharma, Pozuelo de Alar- Ophthalmology. 2008;115:988–92.
cón, Madrid, Spain), is a calcineurin inhibitor generally used 5. Kymionis GD, Klados NE, Kontadakis GA, Mikropoulos DG.
at 0.03% for atopic dermatitis. The presence of excipients (pro- Treatment of superior limbic keratoconjunctivitis with topical
pylene carbonate) in the skin cream gives rise to doubts about tacrolimus 0.03% ointment. Cornea. 2013;32:1499–5015.
ocular surface toxicity although literature references report 6. Wang C, Lin A. Efficacy of topical calcineurin inhibitors
in psoriasis. J Cutan Med Surg. 2014;18:8–14.
goods tolerance in anterior segment diseases refractory to